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ABSTRACT  
The discovery and identification of the human epidermal growth factor receptor 2 (HER’s-2) genes, have led to a better understanding of breast 
tumour biology. A member of the epidermal growth factor receptor family, it is a potent mediator of cellular growth and proliferation in malignant 
epithelial cells. Amplification or over expression of HER-2 occurs in approximately 15–30 % of breast cancers and 10–30 % of 
gastric/gastroesophageal cancers and serves as a prognostic and predictive biomarker. Treatment with HER-2 targeted monoclonal antibody, 
trastuzumab dramatically improved outcome in patients with breast malignancy. This promising approach led to the development of pertuzumab, 
ado-trastuzumab emtansine and lapatinib. The development of drug resistance and disease progression due to alternate signalling remained a real 
therapeutic challenge. Several research studies are currently focused on inhibition of onco-proteins, kinases and growth factors linked to HER-2 
positive breast cancers. The success of immune checkpoint modulators and vaccines in preliminary studies describes the role of tumour immunity. 
Apart from its role in the pathogenesis of various cancers, HER-2 directed therapeutic approach has brought about a revolutionary change in terms 
of time to progression and survival rates in breast cancers. 
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INTRODUCTION  
Breast cancer is the most common invasive cancer diagnosed in 
women. In spite of early treatment and improved therapy, it is the 
second leading cause of cancer-related deaths in women after lung 
cancer. Global incidence of the disease is increasing lately owing to 
better awareness and early detection. India holds the maximum 
number of women dying of breast cancer. [1] However death rates 
dropped during the 1980s when hormonal therapy directed against 
oestrogen and progesterone positive breast cancer was discovered. 
Research in the last decades has led to a better understanding of the 
intricate molecular heterogeneity of this malignancy. One such 
promising approach was the discovery of HER-2 gene and 
identification of an antibody against it in the late 1990s.  
The success of trastuzumab in the treatment of advanced metastatic 
breast cancer has not only led scientists in developing newer 
molecules and targets against HER-2, but also has been looked as a 
therapeutic option in other malignancies too. A detailed explanation 
of HER-2 gene expression in cancer, receptor signalling and 
detection methods have been carried out. This review article also 
best describes the currently available HER-2 directed therapies, 
newer molecules and strategies to overcome resistance to 
trastuzumab therapy. 
HER-2/NEU gene  
HER-2 gene is expressed in 20%-30% of breast cancers. The 
oncogene has numerous synonyms like HER-2/Neu/ErbB-2 and 
p185 depending upon its origin from the cell line and similarity to 
other genes. Amplification and overexpression of HER-2 has been 
associated with invasion and progression of gastric and other 
malignancies also. Since HER-2 activity plays a critical role in the 
maintenance of breast neoplastic proliferation, HER-2 directed 
therapies have always been an area of interest for treating 
malignancies since its discovery [2]. HER-1, the first in the 
tyrosine kinase family to be discovered by Stanley Cohen et al. in 
1978. The proto-oncogene Neu was first discovered by Weinberg 
RA et al. in 1982. Later renamed as HER-2 because of its 
structural similarity to HER-1. It was termed as Neu initially 
since it was first identified in rodent glioblastoma, a neural 
tumour. The gene was also termed as ErbB-2 by Yamamoto et al. 
in the year 1984 as they had found it in avian erythroblastosis 
oncogene B (ErbB) which codes for the human epidermal growth 
factor. A group of scientists in 1986, Ullrich and Coussens, 
cloned the Neu oncogene, sequenced and mapped it to human 
chromosome 17. The gene is also known as p185 as it encodes a 
phosphoprotein of 185,000 Dalton. Its association with human 
mammary carcinoma in terms of poor prognosis and survival 
was evidenced by Slamon et al. in 1987 [3]. 
HER-2 dysregulation 
Deregulation of HER-2 signalling stimulates cancer cells to develop 
and spread. These are consequences of two important events. HER-2 
gene amplification in cancer cells leads to an excess of the HER-2 
protein. HER-2 receptor overexpression on the cell surface is 
responsible for activation of signalling pathways. The Greater 
magnitude of membrane receptors also evades endocytic 
degradation of receptors linking to a pathway of increased potency 
and signalling [3]. HER-2 protein over expression or gene 
amplification serves as a guide for chemotherapy choice, antibody 
therapy, outcome and prognosis in breast carcinoma [4]. 
HER-2 receptor 
Classification: HER-2/neu protein belongs to a four-member 
family of closely related growth factor receptors. They play a key 
role in the pathogenesis of several human cancers. The family is 
composed of four main members: HER-1, HER-2, HER-3 and 
HER-4, also called ErbB1, ErbB2, ErbB3 and ErbB4 respectively. 
All four HER receptors are comprised of an extracellular ligand 
binding site, a lipophilic transmembrane segment and an 
intracellular domain with tyrosine kinase catalytic activity. HER-
1 is activated by epidermal growth factor, transforming growth 
factor alpha, betacellulin and epiregulin [5].  
Heregulins, specific for HER-3 and HER-4 is endogenous ligands 
falling under a group of proteins called neuregulins which are 
closely linked to the HER family. They bind and activate receptors 
responsible for cardiac and neural development during 
embryogenesis and play an important role in carcinogenesis. [6] 
However, HER-2 has no known direct activating ligand and may be 
at an activated state constitutively or become active upon 
heterodimerization with other family members such as HER-1 and 
HER-3.  
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 4, 2016 
Nayak et al. 




Understanding the structure of HER-2 enables us to know its 
involvement in signalling mechanisms and receptor targeted 
therapies. Each HER-2 receptor is composed of four subdomains. 
Sub-domain I is in continuous contact with sub-domain III. The 
permanent interaction between these 2 sub-domains keeps the 
receptor in an open conformation, exposing sub-domain II. This 
ensures that sub-domain II (dimerization domain) is always open 
and ready to dimerize and bind with other receptors in the HER 
family to initiate downstream signalling. Sub-domain IV stabilizes 
and locks the receptor in an activated state [5]. In therapies 
targeting HER-2, there are drugs like pertuzumab and trastuzumab 
that bind to sub-domain II and IV respectively to interfere with HER-
2 signalling [7]. 
Function 
HER receptors exist as monomers on the cell surface. Upon ligand 
binding to their extracellular domains, HER proteins undergo 
dimerization, autophosphorylation of tyrosine residues and initiate 
a variety of signalling pathways. They regulate cell growth, survival 
and differentiation. Heterodimers containing HER-2 have the high 
ligand binding capacity and generate more potent signals as HER-2 
exists in an open conformation making it the dimerization partner of 
choice among the family members. HER-2-HER-3 heterodimer is the 
most potent stimulator of downstream events, particularly the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway. 
Signaling 
Stimulation by growth factors causes phosphorylation of PI3K. 
Activated PI3K, phosphorylates lipids on the plasma membrane, 
forming second messenger phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). Akt, a serine/threonine kinase resides in the 
cytosol in an inactive state. With the release of second messenger 
PIP3, it is translocated to the plasma membrane where it causes 
conformational changes and exposure of phosphorylation sites. Cell 
survival, growth, proliferation, cell migration and angiogenesis are 
mediated by phosphorylating a range of intracellular proteins like 
mTOR (mammalian target of rapamycin). Cell survival is potentially 
mediated through this pathway as there is phosphorylation of pro-
apoptotic genes. The PI3K-Akt pathway has many downstream 
effects and must be clearly regulated. One of the ways the pathway is 
negatively regulated is by reducing PIP3 levels. Phosphatase and 
tensin homolog (PTEN) antagonises PI3K by converting PIP3 into 
PIP2. Loss or mutation of PTEN function common in cancer cells 
leads to over-activation of Akt. In malignancy, excess PI3K-Akt 
activity regulates PTEN levels by affecting its transcription and 
activity. Nuclear factor kappa B (NF-κB) activated by Akt, release 
tumor necrosis factor α (TNFα) which in turn repress PTEN 
expression [7]. The RAS/RAF/MAP kinase is another important 
pathway to be stimulated in HER-2 signalling which is associated 
predominantly with cell proliferation. RAF kinase activated by RAS 
phosphorylates and activates a mitogen-activated protein kinase 
(MAPK). RAF and MAPK are both serine/threonine-selective protein 
kinases. MAPK governs the activities of several transcription factors 
like microtubule-associated protein (MAP). A third significant factor 
in the network is a protein kinase, which is activated by 
phospholipase C. Protein kinase can activate MAPK pathway 
bypassing RAS and bring about cell adhesion, migration, 
proliferation and survival [8, 9]. 
HER-2 expression in cancer  
HER-2 has been expressed in over 15%-30% of invasive breast 
cancers. It serves as a prognostic determinant as well as a predictor 
of therapeutic response. It is correlated to tumour size, tumour 
stage, lymph node involvement and metastasis. [10]Not only HER-2 
positivity is associated with brain metastasis, but it is also an 
important event occurring very early in the pathogenesis of tumour 
spread. [11]The risk of recurrence with HER-2 positivity is 9.5 times 
greater and is a predictor of overall survival rate and time to relapse. 
[8]HER-2 amplification in tumour cells responds to HER-2 directed 
therapy. It is associated with increased sensitivity to anthracycline 
group of chemotherapeutic agents like doxorubicin. HER-2 gene is 
closely situated near topoisomerase gene which is a target for 
anthracycline group of drugs. It can up regulate them by a mechanism 
called as receptor enhanced sensitivity. [12]HER-2 positivity is linked 
to the absence of oestrogen and progesterone receptor causing 
resistance to hormonal agents. There exists a bi-directional link 
between HER-2 and hormone receptor pathway playing an important 
role in a combination of therapy as well as in the development of 
resistance. (fig. 1) Drugs which interfere with HER-2 signalling can 
reverse resistance to tamoxifen. On the other hand, oestrogen can 
inhibit the transcription of HER-2 promoter genes and decreased 
expression of HER-2 receptors in mammary tissue [13, 14]. 
 
 
Fig. 1: Bi-directional link between HER-2 and hormone receptor in breast cancer therapy 
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HER-2 is a key biomarker of gastric cancer expressed in 6% to 33% 
of cases. HER-2 overexpression is generally found in 
adenocarcinoma, junctional gastroesophageal tumours and diffuse 
carcinoma. Its positivity is associated with tumour size, serosal 
invasion and lymph node metastasis. [15] With increasing 
understanding of HER-2 science, it has now been acknowledged that 
HER-2 overexpression occurs in other forms of cancers also such as 
ovarian, endometrial, colon, bladder, lung, head and neck carcinoma. 
[8] Apart from its role in the development of diverse cancers, it has 
also been intensely evaluated as a therapeutic target. 
Testing for HER-2 
There is a necessity for the accurate determination of HER-2 status 
for guiding therapy, getting impressive results and to prevent the 
development of resistance. The available methods are southern 
blotting, immunohistochemistry (IHC), enzyme immunoassays, 
polymerase chain reaction (PCR) and fluorescence in situ 
hybridization technique (FISH). Literature shows that 20% of 
current HER-2 testing are inaccurate. The American Society of 
Clinical Oncology (ASCO) and the College of American Pathologists 
(CAP) in the year 2007 have set up guidelines for analysis of HER-2 
testing. They approved IHC assay and FISH technique for estimation 
of HER-2 status in order to improve reliability and efficacy and to 
avoid confusion between test centres. [16] IHC assays determine 
protein expression. Built on the intensity of membrane staining they 
can be positive (3+) or negative (0 or 1+) for HER-2.  
Cancer specimens with the equivocal (2+) score are submitted for 
confirmation with the FISH technique. The scoring technique for 
FISH is based on the number of gene copies and ratio of the receptor 
(Her-2)-to-centromere probe for chromosome 17 (CEP17). Positive 
HER-2 amplification are suitable candidates, while if negative they 
are not considered for HER-2 therapy. Patients with equivocal HER-
2 amplification with the FISH technique should undergo further 
retesting. [17, 18] Gastric cancers are associated with high intra-
tumoral heterogeneity and insufficient staining of cancer cells, due 
to which scoring system used for breast cancer, cannot be 
considered in this tumour. The national comprehensive cancer 
network (NCCN) panel has set a separate scoring system based on 
basolateral membrane staining. [19] 
HER-2 targeted therapy  
Trastuzumab 
Since the identification of HER-2 gene in 1984 and association of 
HER-2 amplification with human breast carcinoma in 1985, a 
monoclonal antibody that binds to domain IV of the extracellular 
segment of the HER-2 receptor was then developed in 1992. The 
humanized monoclonal antibody, trastuzumab received its approval 
in 1998 for the treatment of metastatic breast cancer. In 2005, it was 
demonstrated that trastuzumab reduced the risk of recurrence in 
early stage cancer. Thus in 2006, it received its approval as an 
adjuvant therapy regimen with doxorubicin, cyclophosphamide and 
paclitaxel for women with node-positive, early stage HER-2 
expressing breast cancer for a period of one year. Results of meta-
analyses have revealed the efficacy of an adjuvant treatment of HER-
2 directed therapy in terms of improved disease-free survival rate, 
decrease the incidence of local and distant metastasis as well as 
superior in terms of reducing overall mortality. [20, 21] In 2010, it 
was also approved in combination with cisplatin and a 
fluoropyrimidine (either capecitabine or 5-fluorouracil) for HER-2 
expressing metastatic gastric or gastroesophageal junction 
adenocarcinoma. The results were based on the TOGA (Trastuzumab 
for gastric cancer) trial where overall median survival rate was 13.8 
mo in the trastuzumab arm compared with 11.1 mo in the 
chemotherapy alone arm. Improvements were seen in terms of 
tumor response, time to progression and duration of response to 
trastuzumab in gastric cancer. [22] 
Proposed mechanisms of actions include [23, 24] 
• Inhibition of HER-2 shedding, where the extracellular segment is 
cleaved off and a p95HER-2 truncated active form of the receptor is 
viewed.  
• Antibody-dependent cellular cytotoxicity (ADCC) is an important 
immune mechanism of tumour lysis owing to infiltration of natural 
killer cells around the drug.  
• Inhibit dimerization of HER-2 receptors with HER-3 or HER-1 
and inactivate the pathway.  
• Negatively regulates PI3K-AKT pathway by inhibiting 
phosphorylation of PTEN a tumour suppressor gene.  
• Inhibits tumour angiogenesis by decreasing vascular endothelial 
growth factor. 
An initial loading dose of 4 mg/kg, followed 2 mg/kg weekly is 
regarded as the standard treatment dose for breast cancer. However, 
a higher dosage is required for gastric cancer. Taken from the 
experiences of TOGA trial, a 3 w schedule (loading dose of 8 mg/kg 
followed by 6 mg/kg weekly) or weekly schedule (loading dose of 4 
mg/kg, 2 mg/kg weekly) is currently recommended for HER-2 
positive gastric/gastroesophageal cancer. Increased drug clearance, 
advanced tumor stage and pharmacologic resistance are causes of 
high dose requirement. [25] Apart from the development of 
resistance, the major problem is heart dysfunction with trastuzumab 
therapy. Fever, nausea, vomiting, infusion reactions, myalgia and 
infections are the most common adverse events. However, these 
adverse events are not of major concern. But the development of 
cardiotoxicity is the most severe life-threatening adverse reaction of 
trastuzumab. It can be asymptomatic with low LVEF, abnormal ECG 
or can present with new onset myocardial infarction, 
cardiomyopathy and signs of heart failure. It is extremely important 
to monitor cardiac function before as well as post chemotherapy. It 
is a possibility that HER-2 protein is essential for cardiac 
development at the time of embryogenesis, and immune-mediated 
destruction occurs with trastuzumab therapy. The risk is also 
increased if underlying cardiac dysfunction pre-exists or when other 
chemotherapeutic cardiotoxic drugs like doxorubicin, 
cyclophosphamides are co-administered. [26] Recovery of 
cardiotoxicity is reversible with withdrawal and timely management. 
However, 2/3rd  of patients do not recover and evaluation of Troponin 
I predicts recovery from cardiac dysfunction. [27] 
Lapatinib 
To overcome the resistance with trastuzumab, a new drug targeting 
HER-1 in addition to HER-2 was identified. This dual tyrosine kinase 
inhibitor Lapatinib received its approval in 2007 as a combination 
therapy with capecitabine for HER-2 overexpressing metastatic 
breast cancer patients, who have already received therapy 
previously with trastuzumab. Approval was based on the delay in 
progression of the disease. Unlike trastuzumab, it is orally active, 
dual acting and binds to the inner segment of the receptor, leading to 
complete inhibition of downstream signalling pathways [28]. It is 
administered at a dose of 1250 mg orally for 21 d along with 
capecitabine. The drug crosses the blood-brain barrier thereby 
having a promising role in brain metastasis. Lapatinib was also 
approved in 2010 as combination therapy with letrozole in 
postmenopausal women. The advantage was observed in terms of 
greater progression-free survival and overall response rate [29].  
Lapatinib is comparatively a safer drug, with the incidence of cardiac 
toxicity being low. Some widespread adverse effects are diarrhoea, 
rash, nausea and anaemia. Most of them are mild to moderate. 
Severe ones include hand-foot syndrome, liver dysfunction and 
cardiac dysfunction in the form ECG changes or asymptomatic low 
LVEF [30]. Even though lapatinib offers an advantage in several 
ways, confusion still exists on switching the therapy to lapatinib or 
prolonging treatment with trastuzumab. However, p95HER-2 form 
of trastuzumab and cells with a mutation PTEN gene responds to 
lapatinib in-vitro and in-vivo [31]. 
Pertuzumab 
After the introduction of two HER-2 antagonists, for almost half a 
decade no drug directing HER-2 came into the market. The discovery 
of two monoclonal antibodies has brought about a revolutionary 
change in the treatment of HER-2 positive breast cancer. The new 
molecule pertuzumab is a humanised monoclonal antibody, binds 
Nayak et al. 
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subdomain II of the extracellular segment of receptor and inhibits 
ligand-dependent HER-2 dimerization and signalling. Like 
trastuzumb it activates ADCC but differs from it in terms of the 
binding site. Even though their binding site is different, they have a 
similar and complementary mechanism of action [32]. It was 
approved in 2012, in combination with trastuzumab and docetaxel 
in HER-2 positive metastatic breast cancer patients previously not 
treated with hormone therapy or chemotherapy. The approval was 
based on the results of Cleopatra trial which showed an increase in 
progression-free survival rate and fewer side effects [33]. 
Pertuzumab is given every 3 w at a dose of 840 mg followed by 420 
mg as IV infusion for one hour. It can also be administered as a fixed 
dose of 1050 mg, as pharmacokinetic parameters do not vary much. 
Common adverse effects include alopecia, diarrhoea, nausea and 
neutropenia. The drug is comparatively safer with the incidence of 
asymptomatic left ventricular dysfunction being 0.3%. Sometimes 
infusion-related reactions and anaphylaxis can be dangerous [34].  
Ado-trastuzumab emtansine (T-DM1) 
Trastuzumab’s role in breast cancer was well established in terms of 
disease progression and survival. A synergistic combination of a 
monoclonal antibody with a chemotherapeutic drug emtansine 
(DM1) was a novel approach to overcome trastuzumab resistance 
and improved cytotoxic killing of tumour cells. T-DM1 is the first 
antibody-directed chemotherapy approved for HER-2 positive 
breast cancer in 2013, as a single agent who has already received 
trastuzumab and a taxane either separately or in combination. 
Approval was based on improvement in overall survival rate and 
fewer side effects seen in EMILIA trial, where ado-trastuzumab was 
compared to lapatinib plus capecitabine. [35]Emtansine is a product 
of isolated plant product maytansine. It is a highly potent 
microtubule inhibitor. Clinical use is restricted by toxicity. However, 
it is covalently linked to trastuzumab via a hetero bifunctional stable 
linker which restricts the systemic spread and reduces toxicity. 
Maximum tolerated dose is 3.6 mg/kg as an infusion every 3 w. 
Cases of thrombocytopenia, liver dysfunction, were observed in 
clinical studies. At therapeutic doses fatigue, nausea, 
musculoskeletal pain and constipation were observed. Keeping the 
doses at a lower range, grade 3 or 4 peripheral neuropathy can be 
prevented [36]. 
Problems of HER-2 therapies  
HER-2 directed therapies have made its mark in the field of breast cancer 
and has brought about a revolution in terms of treatment and outcome. 
Until recently, issues on HER-2 testing were the principal concern.  
However, after the implementation of guidelines, it has become clear 
that therapy needs to be initiated if tested positive. Accurate testing 
is necessary to avoid false negative results, where patients will be 
deprived of HER-2 therapy which might bring out a dramatic change 
in terms of outcome and survival. At the same time, it is also 
important to identify false positive cases, where the patients will be 
subjected to unnecessary medications, cost and toxicity.  
It is more than a decade since trastuzumab has been approved and 
provided excellent results in millions of women suffering from one 
of the most common cancers-breast malignancy. Fastest research is 
occurring in the field of HER-2, and more molecules targeting HER-2 
pathways are being subjected to in-vitro and in vivo studies. This is 
of utmost importance, where the real challenge faced in clinical set 
up is the development of primary and acquired resistance seen in 
66%-88% of cases. Either therapy needs to be changed to another 
drug targeting HER-2 or combined with other drugs to supplement 
its action and overcome resistance [37, 38].  
Numerous mechanisms have been postulated in preclinical studies 
[39, 40]. Knowledge of the underlying mechanisms will guide in the 
identification of novel molecules, new targets and alternate pathway 
inhibitors for HER-2 in breast cancer. 
  
Table 1: Mechanisms of Trastuzumab resistance in the treatment of HER-2 positive breast cancers 
Mechanisms Alterations  Consequence  
Interference of antigen-antibody 
interaction 
Proteolytic cleavage of extracellular domain of HER-2 Mutated active truncated p95HER-2 
isoform 
Epitome masking Expression of glycopeptide Mucin-4 and CD44, a 
transmembrane receptor for hyaluronan 
Masking of antigen binding site on HER-2 
receptor  
Alternate HER family pathway 
signalling  
Overexpression of HER-1, HER-3 and HER-4 Overcome trastuzumab-mediated 
inhibition of HER-2 signalling 
Compensatory signalling of 
tyrosine kinase family 
Expression of Insulin-like growth factor-1R, tyrosine kinase c-
Met gene 




Phosphatase and tensin homolog deficiency/mutation Active PI3K/AKT pathway, by loss 
inhibiting hydrolysis of PIP3 




Tyrosine kinase inhibitors 
Introduction of drugs lapatinib and pertuzumab was to overcome 
resistance with trastuzumab. The involvement of other receptors in 
the HER family in addition to HER2 signalling led to the discovery of 
these molecules. Lapatinib also is HER-1 family inhibitor along with 
HER-2, whereas pertuzumab inhibits dimerization with HER-3 
receptor by binding to the dimerization domain, thereby controlling 
escape pathways of activation. Based on the same principle, two 
different tyrosine kinase inhibitors are being studied in phase 3 trials, 
showing promising results in terms of response and survival [41]. 
Neratinib, like lapatinib, is an oral tyrosine kinase inhibitor directing 
towards EGFR/HER-1 and HER-2. However, covalent binding to the 
receptor makes it irreversible. It is under evaluation for locally 
advanced and metastatic breast cancer. The benefit was seen in 
terms of improvement in progression-free survival rate in naive 
trastuzumab patients and previously treated patients. The incidence 
of cardiotoxicity is less. Maximum tolerated dose is 340 mg with 
severe diarrhoea being the dose-limiting toxicity requiring 
discontinuation or conservative treatment. Afatinib is another orally 
active irreversible inhibitor like neratinib, inhibiting EGFR/HER-1, 
HER-2 and HER-4 family of tyrosine kinases. It is also being studied 
in phase 3 trials for advanced breast cancer along with vinorelbine 
in comparison to trastuzumab [42, 43]. 
PI3K/Akt/mTOR pathway inhibitors 
In breast cancer, until now the monoclonal antibodies and tyrosine 
kinase inhibitors are approved and those under phase 3 trials target 
the HER receptor per se, giving a chance for alternating signals and 
oncogene to stimulate PI3K/Akt/mTOR pathway. To overcome 
resistance, molecules are developed so as to target directly the 
pathway without involvement of receptor. Several PI3K/Akt 
inhibitors to target PI3K/Akt mutations are in preclinical studies 
[44]. The most promising drug is everolimus, a mTOR inhibitor 
being investigated in a phase 3 trial along with trastuzumab and 
vinorelbine for breast cancer patients refractory to trastuzumab. 
Everolimus arm had greater time to progression of disease [45]. 
Heat shock protein 90 (HSP90) inhibitors 
A novel therapeutic approach is degradation of HER-2 receptors by 
using HSP90 inhibitors. Overexpression of HSP90 is associated with 
Nayak et al. 
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treatment resistance and worse prognosis in breast malignancy. 
Heat shock proteins are a group of molecular chaperones involved in 
evolution, stability and folding of oncoproteins. At the time of stress, 
malignant cells depend on HSP for signal transduction, cell cycle 
regulation and apoptosis. [46] Inhibitors of HSP like tanespimycin, 
ganetespib as monotherapy or combination therapy have shown 
modest clinical benefit in phase 2 studies. Hepatotoxicity was the 
dose-limiting toxicity with these agents. Ganetespib is more potent 
with fewer side effects [47]. 
Vascular endothelial growth factor (VEGF) inhibitors 
Anti-angiogenic drugs have always had a crucial role to play in any 
cancer. Growth factors of neovascularization associate with HER-2 in 
the pathogenesis, survival and spread of tumour cells. [48] Anti-
VEGF antibody-like bevacizumab, are being evaluated in phase 3 
studies as add-on therapy for breast cancer. Bevacizumab arm has 
shown improvement in progression-free survival rate. Cardiotoxicity 
in terms of hypertension and heart failure is a major limiting factor. 
Sunitinib an orally effective tyrosine kinase inhibitor against VEGF 
was also tried in HER-2 positive cancers. Numerous phase 3 studies 
showed only increased cases of dermatological toxicity and poorer 
therapeutic outcome [49]. 
Insulin-like growth factor-1 (IGF-1) inhibitors 
IGF-1 and HER-2 are always a linked pathway in PI3K/AKT 
signalling in breast cancer, especially where IGF-1 is associated with 
the mechanism of resistance. IGF-1 can cause phosphorylation of 
HER-2 in malignancy even when an anti-HER-2 drug like 
trastuzumab is administered. Inhibition of IGF-1 signalling along 
with HER-2 inhibition in combination therapy can overcome 
resistance to trastuzumab [50]. As per the results of pre-clinical 
studies, Cixutumumab, an IGF-1 inhibitor has been considered for 
clinical trials in breast malignancy [51]. 
Immune checkpoint modulators 
Modulating the negative regulators of the immune system by 
developing antibodies directed towards them have shown a 
promising approach in the field of cancer therapy. Programmed 
cell death protein 1 (PD 1) and Cytotoxic T-lymphocyte-
associated antigen 4 (CTLA 4) are immune checkpoint proteins, 
down regulating the immune system. PD 1 suppresses 
autoimmunity and activation of T cells in the periphery. CTLA 4 
causes downregulation of helper T cells and up regulates 
immuno-suppressive regulatory T cell. The immune system plays 
a major role in the degradation of tumour cells by activation of T 
cells. The similar mechanism underlies the action of trastuzumab 
by induction antibody dependent cytotoxicity. It was noted that 
higher the infiltration of lymphocytes around the malignant cells, 
better the tumour responded to trastuzumab in in-vitro studies 
[52]. By targeting antibodies against these immune checkpoint 
modulators, the immune response against tumour cells can be 
upgraded and finally assist in the treatment of breast 
malignancy. Anti-CTLA4 antibody (ipilimumab) and anti-PD1 
antibodies are in various stages of a clinical trial for breast 
cancers [53]. 
HER-2 vaccines 
Induction of humoral and cellular response against cancer cells 
through antibody-directed HER-2 therapy has already proven its 
efficacy and results in breast malignancy. The same concept was 
applied in the development of HER-2 vaccines to generate anti-
HER-2 immune responses against HER-2 positive breast tumours 
[54]. Immune responses are induced in patients utilizing HER-2 
antigen protein or DNA. E75 a peptide-based vaccine was 
investigated in HER-2 positive breast cancer, which is the 
extracellular portion of the receptor. Results revealed 2 y survival 
rates of 86% in comparison to just 60% in those without 
vaccination. HLA restriction and immunological tolerance were the 
limitations. Whole tumour cell vaccines developed can be 
autologous or allogenic. Vector-mediated dendritic cell vaccines 
are also available. Poor efficacy and autoimmune reactions were 
few limitations [55]. 
CONCLUSION  
HER-2 gene has been expressed in 15-30% of breast cancer, serving 
as an important biomarker, in terms of therapy and outcome. HER-2 
directed therapy in patients with gastro-esophageal cancers has 
provided remarkable results in terms of survival. Although HER-2 
expression was also found in other malignancies, therapy with HER-
2 antagonists has failed to provide substantial results, where further 
research is needed. HER-2 testing is routinely recommended in 
breast and gastric malignancies. Monoclonal antibodies, tyrosine 
kinase inhibitors and drug conjugates have been developed and 
approved for HER-2 positive malignancies. The first monoclonal 
antibody introduced was trastuzumab against early and metastatic 
breast cancer, followed by lapatinib for patients non-responsive to 
trastuzumb. Two drug entities pertuzumb and T-DM1, are examples 
of antibody and cytotoxic therapy to overcome resistance with 
trastuzumab. One of the real challenges with HER-2 therapy is the 
development of resistance. Newer tyrosine kinase inhibitors target 
additional HER family and mTOR inhibitors interfering the pathway 
has shown promising results. Stimulation of the immune system to 
attack cancer cells via vaccine or immune checkpoint modulators 
can also be a promising approach. This review highlights the newer 
molecules and targets against HER-2 signalling developed and 
studied for overcoming resistance. The basic concept of introducing 
new targets is based on recognising the underlying mechanisms of 
resistance. The exact role of newer drugs like HSP-90 inhibitors, IGF-
1 inhibitors and VEGF inhibitors in the field of breast cancer cannot 
be commented in view of monotherapy; however they can be 
considered as an option for combination with trastuzumab for 
breast cancer chemotherapy in the near future.  
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